Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 1Gynecologic 1Breast 1

Conditions

Glioblastoma 5Glioma 4Prostatic Neoplasms 3Astrocytoma 3Lung Neoplasms 2Pleural Effusion, Malignant 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Mesothelioma 1Ependymoma 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Carboplatin 98Pemetrexed 70pembrolizumab 68Cisplatin 59Paclitaxel 54Docetaxel 45Gemcitabine 37Erlotinib Hydrochloride 24Nivolumab 23osimertinib 17Bevacizumab 17durvalumab 14Cetuximab 13130-nm albumin-bound paclitaxel 13Gefitinib 11Etoposide 11Drug Therapy 11Ipilimumab 9Injections 9Albumin-Bound Paclitaxel 9Vinorelbine 8Radiotherapy 8motexafin gadolinium 7capmatinib 7atezolizumab 7epacadostat 6Taxes 6Cyclophosphamide 6vandetanib 5entinostat 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Lung Neoplasms × Valacyclovir × Clear all
NCT03131037 2025-07-11

Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer

Candel Therapeutics, Inc.

Phase 1 Completed
12 enrolled
Thoracic

Lung Neoplasms

NCT01997190 2023-08-25

MpeTK01

Candel Therapeutics, Inc.

Phase 1 Completed
19 enrolled
BreastGynecologicOther solid neoplasmThoracic

Breast Neoplasms, Lung Neoplasms, Mesothelioma, Ovarian Neoplasms, Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡